Cellectis (CLLS) Getting Somewhat Positive Press Coverage, Accern Reports

Media stories about Cellectis (NASDAQ:CLLS) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cellectis earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.0915023814459 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

Shares of Cellectis (NASDAQ CLLS) traded up $1.18 during mid-day trading on Friday, hitting $26.65. The company had a trading volume of 394,076 shares, compared to its average volume of 228,200.

A number of equities research analysts have recently weighed in on the company. Jefferies Group LLC reaffirmed a “buy” rating and set a $47.00 price target on shares of Cellectis in a research note on Sunday, October 29th. SunTrust Banks, Inc. downgraded Cellectis from a “buy” rating to a “hold” rating and cut their price target for the stock from $35.00 to $20.00 in a research note on Tuesday, September 5th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $40.00 price target (up from $33.00) on shares of Cellectis in a research note on Tuesday, September 5th. Zacks Investment Research raised Cellectis from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a research note on Tuesday, October 24th. Finally, BidaskClub downgraded Cellectis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $39.50.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/11/05/cellectis-clls-getting-somewhat-positive-press-coverage-accern-reports.html.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Insider Buying and Selling by Quarter for Cellectis (NASDAQ:CLLS)

What are top analysts saying about Cellectis S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cellectis S.A. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit